In CRC cell lines, deltarasin specifically inhibits the proliferation of cell lines with oncogenic KRAS mutations, and the latest generation of the PDEδ inhibitor, deltasonamide 2, shows a more superior suppression effect [96]. Here, PDE6D is linked to colorectal carcinoma.